Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced

Mohammad Omar Faruk Shaikh1,2, Matthew M Schaefers1,2, Christina Merakou1,2

  • 1Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.

Infection and Immunity
|September 7, 2022
PubMed

Insights

A novel vaccine combining Pseudomonas aeruginosa proteins PopB/PcrH and OprF/I enhances protection against pneumonia. This combination elicits functional antibodies, offering a potent strategy against this Gram-negative pathogen.

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Pseudomonas aeruginosa is a Gram-negative pathogen causing hospital-acquired pneumonia.
  • Increasing antibiotic resistance necessitates effective vaccines.
  • Previous work identified PopB protein's potential for intranasal (IN) immunization and protection.

Purpose of the Study:

  • Evaluate the immunogenicity and protective efficacy of a combined PopB/PcrH and OprF/I vaccine.
  • Compare intranasal (IN) and subcutaneous (SC) immunization routes.
  • Assess the functional antibody responses and protection against P. aeruginosa pneumonia.

Main Methods:

  • Mice were immunized with PopB/PcrH, OprF/I, or the combination via IN or SC routes.
  • Assessed Th17 recall response from splenocytes.
  • Evaluated protection in a lethal P. aeruginosa pneumonia model.
  • Measured IgG titers, opsonophagocytic killing activity, and antibody blockade of IFN-γ binding to OprF/I.

Main Results:

  • PopB/PcrH, alone or combined with OprF/I, induced Th17 recall responses.
  • The PopB/PcrH and OprF/I combination provided enhanced protection against lethal pneumonia, irrespective of route.
  • Vaccines generated IgG titers against P. aeruginosa components.
  • Antisera containing OprF/I blocked IFN-γ binding to OprF/I, a virulence factor.

Conclusions:

  • Vaccines combining PopB/PcrH and OprF/I elicit functional antibodies.
  • This combination provides broadly and potently protective immunity against P. aeruginosa pulmonary infections.
  • The developed vaccine strategy targets a critical need for effective P. aeruginosa vaccines.